Lilly launches oral obesity pill

For two years, the weight-loss drug boom has mostly meant weekly shots kept cold in a fridge. On April 1, Eli Lilly got United States approval for Foundayo, a once-daily pill for adults with obesity, and Lilly says it became available nationwide in early April through LillyDirect, retail pharmacies, and telehealth channels. (medical.lilly.com) Foundayo is Lilly’s brand name for orforglipron, a glucagon-like peptide-1 pill. That drug class copies a gut hormone that helps people feel full and eat less, which is why the market has been dominated by injectable brands like Lilly’s Zepbound and Novo Nordisk’s Wegovy. (foundayo.lilly.com, press.aboutamazon.com) The part Lilly is pushing hardest is convenience. The Foundayo label says patients take one tablet once daily, with or without food, and Lilly says it is the only weight-loss glucagon-like peptide-1 pill in the United States that can be taken any time of day without food or water restrictions. (pi.lilly.com, medical.lilly.com) Lilly also priced the first step low enough to get attention. The company’s savings page lists self-pay pricing starting at $149 a month for the 0.8 milligram starter dose, then $199 for 2.5 milligrams, $299 for 5.5 and 9 milligrams, and $349 for 14.5 and 17.2 milligrams. (foundayo.lilly.com, foundayo.lilly.com) That tiered pricing matters because Foundayo is designed like a staircase, not a switch. The prescribing information starts patients at 0.8 milligrams once daily, moves to 2.5 milligrams after at least 30 days, then 5.5 milligrams after another 30 days, with optional increases up to a maximum of 17.2 milligrams. (pi.lilly.com) Amazon moved fast to turn that launch into a delivery fight. Amazon’s press center posted on April 9 that Amazon Pharmacy will offer Foundayo by same-day delivery, after already expanding access in March to Lilly’s injectable Zepbound KwikPen with transparent cash-pay pricing starting at $299 a month for the 2.5 milligram starter dose. (press.aboutamazon.com, press.aboutamazon.com) Amazon has been building the logistics for this for months. Amazon Pharmacy said in February that same-day prescription delivery would expand to nearly 4,500 United States cities and towns by the end of 2026, and its pharmacy pages say same-day service is already available in many locations. (aboutamazon.com, pharmacy.amazon.com) Lilly is not walking into an empty lane. Novo Nordisk says its Wegovy pill became the first approved once-daily oral glucagon-like peptide-1 medicine for chronic weight management and delivered 16.6% weight loss in adherent trial participants, while Novo says its obesity portfolio reached 3.6 million people worldwide in 2025 and held close to 43% of global glucagon-like peptide-1 volume. (annualreport.novonordisk.com, annualreport.novonordisk.com) So the new contest is not just Lilly versus Novo Nordisk on drug chemistry. It is LillyDirect, Amazon Pharmacy, retail pharmacies, telehealth prescribers, and self-pay pricing all competing to make obesity treatment feel less like a specialty procedure and more like filling a blood-pressure prescription. (medical.lilly.com, press.aboutamazon.com, aboutamazon.com) The pill is still not a casual product. Foundayo carries a boxed warning about thyroid C-cell tumors seen in rodents, is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and Lilly’s medication guide warns about nausea, vomiting, and other stomach-related side effects that have defined this whole drug class. (pi.lilly.com, pi.lilly.com)